LGC LGC
  • About us
    • About LGC
    • Leadership team
    • Our locations
    • ESG
    • Reports & documents
  • What we do
    • Diagnostics and Genomics
      • Clinical diagnostics
      • Biosearch Technologies
    • Assurance
      • Reference standards, research chemicals & proficiency testing
      • Supply chain assurance
      • National Laboratories & Science
    • Nucleic Acid Therapeutics
      • Axolabs
  • Careers
    • Our people
    • Careers at LGC
  • News
  • Contact us
Buy from us

Follow us on social media

News

To contact the press office please email or call +44 7408 850 514

NML collaborate to improve quality assessment schemes for Chronic Myeloid Leukaemia Minimal Residual Disease testing

25 January 2024

The National Measurement Laboratory and UK NEQAS for Leucocyte Immunophenotyping announce collaboration to improve quality assessment schemes for Chronic Myeloid Leukaemia Minimal Residual Disease testing.

Read More
LGC Genomics opens new state-of-the-art laboratory facility in North London

16 January 2024

New laboratory officially opened by David Willetts, UK Minister for Universities and Science.

Read More
LGC Biosearch Technologies™ launches a groundbreaking nucleic acid extraction method, sbeadex™ Lightning

15 January 2024

LGC Biosearch Technologies™ launches a groundbreaking nucleic acid extraction method, sbeadex™ Lightning. This groundbreaking product rapidly delivers high-purity DNA in high-yields, typically achieving results in 5 minutes

Read More
LGC mid-year Update: 1 April – 30 September 2023

15 December 2023

LGC announces half year trading results

Read More
LGC acquires PolyDesign

14 November 2023

LGC acquires PolyDesign, a provider of innovative oligo solid support products for life sciences customers.  

Read More
National Measurement Laboratory at LGC supports the UK global leadership in ensuring accurate diagnostics for future pandemics.

02 November 2023

National Measurement Laboratory at LGC supports the UK global leadership in ensuring accurate diagnostics for future pandemics.

Read More
LGC acquires Virusys Corporation.

09 October 2023

LGC Clinical Diagnostics, a business unit of LGC, today announced the acquisition of Virusys Corporation, a developer and manufacturer of monoclonal antibodies and viral antigens.

Read More
LGC Group appoints David King as Non-Executive Director and Chairman

28 September 2023

LGC announced today the appointment of David P. King as Non-Executive Chairman of its Board of Directors.

Read More
Review of methods and challenges associated with detection of Precision Bred Products

18 September 2023

The UK National Reference Laboratory for GMOs based at LGC has reviewed the current state-of-the-art methods for the potential detection of Precision Bred Organisms (PBOs) in food and feed supply chains and to provide recommendations towards developing a framework for the traceability of PBOs.

Read More
LGC acquires Kova International, Inc., including Biochemical Diagnostics, Inc., strengthening its portfolio of Quality Measurement Tools

24 July 2023

Today, LGC Clinical Diagnostics, a business unit of LGC, announced the acquisition of Kova International, Inc. (Kova), a leading developer and manufacturer of in vitro urinalysis and toxicology quality control products for clinical laboratories

Read More
Mehrdad Tabrizi appointed Executive Vice President & General Manager, LGC Axolabs

10 July 2023

LGC today announced the appointment of Dr Mehrdad Tabrizi as Executive Vice President and General Manager for LGC Axolabs.

Read More
DNA identifies five more Australian World War I soldiers

25 April 2023

Five more soldiers who fell at the Battle of Fromelles more than 100 years ago have been identified using DNA analysis performed by LGC.

Read More
  • PREV
  • 1
  • 2
  • 3
  • …
  • 19
  • NEXT
LGC LGC

Contact us

Follow us on social media

About us
  • About LGC
  • Our locations
  • Leadership team
  • ESG
  • Reports & documents
What we do
  • Clinical diagnostics
  • Biosearch technologies
  • Reference standards, research chemicals & proficiency testing
  • Nucleic acid therapeutic services
  • Supply chain assurance
  • National Laboratories & Science
Policies
  • Terms and conditions
  • Privacy notice
  • Cookie policy
  • Data privacy and processing Policy
  • LGC modern slavery statement
Careers
  • Careers at LGC
  • Our people
  • News
  • Contact us

© LGC Limited, 2025.
All rights reserved. All trademarks acknowledged.

LGC Limited Registered in England No. 2991879. VAT No. 674 056 721
Registered office: LGC, Queens Road, Teddington, Middlesex, TW11 0LY, UK

Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}